Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chakravarty, S. Articles by Zavala, F. Search for Related Content PubMed PubMed Citation Articles by Chakravarty, S. Articles by Zavala, F.

 Previous Article  |  Next Article 

Infection and Immunity, August 2008, p. 3628-3631, Vol. 76, No. 8
0019-9567/08/$08.00+0     doi:10.1128/IAI.00471-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Effector CD8⁺ T Lymphocytes against Liver Stages of Plasmodium yoelii Do Not Require Gamma Interferon for Antiparasite Activity

Sumana Chakravarty, G. Christian Baldeviano, Michael G. Overstreet, and Fidel Zavala^*

Department of Molecular Microbiology and Immunology, Malaria Research Institute, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe Street, Baltimore, Maryland 21205

Received 15 April 2008/ Returned for modification 14 May 2008/ Accepted 22 May 2008

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The protective immune response against liver stages of the malaria parasite critically requires CD8⁺ T cells. Although the nature of the effector mechanism utilized by these cells to repress parasite development remains unclear, a critical role for gamma interferon (IFN-) has been widely assumed based on circumstantial evidence. However, the requirement for CD8⁺ T-cell-mediated IFN- production in protective immunity to this pathogen has not been directly tested. In this report, we use an adoptive transfer strategy with circumsporozoite (CS) protein-specific transgenic T cells to examine the role of CD8⁺ T-cell-derived IFN- production in Plasmodium yoelii-infected mice. We show that despite a marginal reduction in the expansion of naive IFN--deficient CS-specific transgenic T cells, their antiparasite activity remains intact. Further, adoptively transferred IFN--deficient CD8⁺ T cells were as efficient as their wild-type counterparts in limiting parasite growth in naive mice. Taken together, these studies demonstrate that IFN- secretion by CS-specific CD8⁺ T cells is not essential to protect mice against live sporozoite challenge.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Studies in rodent malaria models have provided definitive evidence that CD8⁺ T-cell responses against the pre-erythrocytic stages of the malarial parasite Plasmodium play a role in protective immunity. The mechanism by which such a response mediates protection is, however, poorly understood. CD8⁺ T cells can deliver effector responses by a variety of pathways, including perforin/granzyme-mediated killing or the secretion of inflammatory cytokines such as gamma interferon (IFN-) or tumor necrosis factor alpha (TNF-). Of these, a strong case has been made in the literature for the antiplasmodial activity of IFN-. Direct administration of human and mouse IFN- inhibits pre-erythrocytic parasite development in monkeys and mice, respectively (6), and recombinant IFN- prevents hepatic schizogony of Plasmodium falciparum (13) and P. berghei (22) in hepatocyte cultures.

IFN--dependent protection against malaria liver stages can be elicited by immunization with sporozoites or subunit vaccines, as well as by adoptive transfer of parasite-specific T-cell clones (5, 19, 23-25). Other investigators have observed correlations between the requirement for IFN- and CD8⁺ T cells for protective immunity (10, 16, 24, 28). Mice adoptively transferred with a cytotoxic-T-cell clone (28) and immunized with the bite of P. berghei-infected mosquitoes (24) or needle injection of radiation-attenuated sporozoites (5) were not protected if IFN- was neutralized with antibodies during rechallenge. Finally, in two recent studies using genetically attenuated sporozoites, protection was linked to CD8⁺ T cells (10) and was abolished in IFN--deficient and T-cell-deficient mice (16). This abundance of correlative data has led to the general acceptance that CD8⁺ T cells secrete IFN- in order to execute protective function against malaria liver-stage parasites.

However, the need for CD8⁺ T-cell-derived IFN- has never been formally demonstrated and, in fact, some studies have shown that CD8⁺ T-cell-mediated immunity against liver-stage parasites is independent of IFN-, both in vitro (8, 9) and in vivo (19). Thus, it is still unclear whether IFN- secretion by antiparasite CD8⁺ T cells is required for elimination of Plasmodium liver stages. We address this issue by using a mouse model system with Plasmodium yoelii where CD8⁺ T cells are the sole mediator of antisporozoite immunity. Unlike previous approaches that globally ablated IFN- using neutralizing antibodies or genetic knockouts, an adoptive transfer strategy allowed us to directly compare the competency of IFN--deficient and normal effector CD8⁺ T cells with regard to their in vivo antiparasite activity.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Mice. Five- to eight-week-old female BALB/c mice were purchased from Taconic (Hudson, NY). Transgenic mice expressing a T-cell receptor (TCR) specific for the SYVPSAEQI epitope of the P. yoelii circumsporozoite (CS) protein were derived as previously described (20). Mice that have previously been backcrossed to the Thy1.1⁺ BALB/c background for >20 generations were used from our colony. BALB/c-Ifng^tm1Ts mice homozygous for the Ifng^tm1Ts targeted mutation were purchased from Jackson Laboratories. These were crossed to CS-specific TCR transgenic mice from our colony and F₁ progeny positive for the TCR transgene were crossed back to BALB/c-Ifng^tm1Ts mice to obtain TCR transgenic mice homozygous for the Ifng^tm1Ts targeted mutation. Genotyping protocols were followed as outlined elsewhere (http://jaxmice.jax.org/pub-cgi/protocols/protocols.sh?objtype=protocol&protocol_id=228). All experimental procedures involving mice were approved by the Institutional Animal Care and Use Committee of the Johns Hopkins University.

Immunizations. Generation of the recombinant vaccinia virus expressing the 9-mer SYVPSAEQI epitope (VV-CS) has been described previously (11, 18). VV-CS was diluted in Hanks balanced salt solution containing 1% heat-inactivated mouse serum to appropriate concentration and delivered intravenously in 200 µl.

Cell isolation. Single cell suspensions of splenocytes were obtained by mechanical disruption of spleens between two microscope glass slides and filtering through 100-µm-pore-size nylon mesh. To isolate intrahepatic lymphocytes, livers were disrupted mechanically, suspended in Hanks balanced salt solution with 2% fetal calf serum and 10 mM HEPES and filtered through a 150-µm-pore-size mesh. This cell suspension was centrifuged, and the pellet was resuspended in a solution of Percoll (Amersham Biosciences) as described previously (12), centrifuged at 500 x g, and washed extensively before use. Where necessary, purified populations of CD8⁺ T cells were obtained by using the mouse CD8⁺ T-cell isolation kit according to the manufacturer's instructions (Miltenyi Biotech, Bergisch Gladbach, Germany).

Adoptive transfers. For adoptive transfer experiments using naive cells, mice received 10⁶ naive TCR-Tg CD8⁺ T cells isolated from the spleens of TCR-Tg wild-type (WT) or IFN- knockout (IFNKO) mice. The proportion of tetramer⁺ CD8⁺ T cells was calculated by flow cytometry, and 10⁶ transgenic cells were transferred into congenic recipient mice. For experiments involving transfer of activated/effector CD8⁺ T cells, we first transferred 10⁶ naive transgenic cells into congenic mice, which were then immunized with 5 x 10⁶ PFU recombinant vaccinia virus carrying the SYVPSAEQI epitope (VV-CS). Fourteen days later, activated CD8 T cells were isolated from the spleens of these mice as described above, the number of tetramer⁺ cells was quantified, and 2 x 10⁶ cells were transferred into recipient mice.

Tetramer and ELISPOT analysis. Enzyme-linked immunospot (ELISPOT) assays to measure SYVPSAEQI-specific interleukin-2 (IL-2)-secreting cells were performed essentially as described previously (2) with modifications to exclude IL-2 addition to the medium during peptide stimulation in vitro.

Parasite quantification in the liver. In challenge experiments, live P. yoelii (17XNL) sporozoites were inoculated intravenously, and 40 h later the livers were harvested, the total RNA was isolated, and the parasite burden in the liver was quantified by using reverse transcription (RT), followed by real-time PCR as outlined previously (1).

Data acquisition and analysis. Fluorescence-activated cell sorting (FACS) data was acquired on a FACSCalibur machine and analyzed by using CellQuest software (Becton Dickinson). ELISPOT plates were read with an immunospot plate reader, and the data were analyzed by using immunospot software (Cellular Technology, Ltd., Cleveland, OH). Graphs were prepared and analyzed by using GraphPad software (GraphPad Software, Inc., San Diego, CA). A Student t test was used for pairwise comparisons to determine statistical significance.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Naive IFN--deficient CD8⁺ T cells are primed against CS. To avoid ambiguities regarding the specific mechanisms that may be involved in generating an effective immune response against malaria liver stages, we generated effector CD8⁺ T cells by immunization with a vaccinia virus that expresses the SYVPSAEQI epitope of the P. yoelii CS protein (i.e., VV-CS). Therefore, in this experimental model, CD8⁺T cells against this epitope are the only effector cells that can possibly recognize parasite antigens after challenge of immunized mice. In previous studies we have shown that vaccinia virus expressing the CS epitope alone—and not WT virus—activates the SYVPSAEQI-specific CD8⁺ T cells (18). To facilitate the tracking of antigen-specific T cells, WT and IFNKO TCR-transgenic CD8⁺ T cells specific for the major histocompatibility complex (MHC) class I-restricted SYVPSAEQI epitope of the P. yoelii CS protein (TCR-Tg) were used. We first evaluated the induction phase of the immune response and compared the capacity of normal and IFN--deficient CD8⁺ T cells to mount a response after immunization. BALB/c mice received WT or IFNKO CD8⁺ T cells and were immunized with VV-CS. Eight days later, lymphocytes were isolated from the spleens and livers, and the CD8⁺ T-cell response was evaluated by FACS using tetramer staining and an ELISPOT assay to detect IL-2-secreting cells since IFN- production could not be used to evaluate T-cell activation. In response to immunization with VV-CS, there was a major increase in the number of both WT and IFNKO CD8⁺ T cells as detected by tetramer staining (Fig. 1a). However, the clonal burst of the IFN- deficient CD8⁺ T cells was diminished compared to WT cells: the percentages of IFNKO TCR-Tg cells on day 8 were 39% of the WT in the spleen and 61% in the liver. Similar reductions were observed in the number of IL-2-producing cells, with the response of IFNKO cells being lower than their WT counterparts in the spleen (40%) and liver (60%) (Fig. 1b). Thus, in this model, naive IFN--deficient CD8⁺ T cells can be efficiently primed, although the response is less robust than that of naive IFN--sufficient T cells.

View larger version (16K): [in this window] [in a new window]

FIG. 1. (a) BALB/c mice received TCR-Tg cells obtained from WT or IFNKO transgenic mice and were immunized with 2 x 106 vaccinia virus. Eight days later, the number of tetramer+CD8+ cells was determined by FACS analysis and is plotted as a proportion of total CD8+ cells within splenocytes and hepatic lymphocyte populations. (b) IL-2-secreting cells within the same populations were identified by ELISPOT assay. Histograms represent means ± the standard errors of the mean (n = 4).

Effector IFN--deficient CD8⁺ T cells are protective. We next evaluated the antiparasite activity exerted by IFN- deficient CD8⁺ T cells compared to WT cells. Similar to the previous experiment, WT and IFNKO CD8⁺ T cells were transferred into naive BALB/c mice, which were then immunized with VV-CS. Eight days later, the mice were challenged with live P. yoelii sporozoites, and the parasite load in the liver was evaluated by RT-PCR 40 h thereafter. Unexpectedly, the parasite load was reduced to similar extents in immunized mice harboring either WT or IFNKO CD8⁺ T cells (Fig. 2a). Thus, in spite of a quantitatively reduced response of IFNKO CD8⁺ T cells during immunization, these cells limited parasite development in the liver to a degree equal to that of WT cells. Any difference in parasite growth between mice harboring WT or IFNKO CD8⁺ T cells was statistically insignificant.

View larger version (12K): [in this window] [in a new window]

FIG. 2. (a) BALB/c mice received TCR-Tg CD8+ T cells isolated from WT or IFNKO mice and were immunized with 2 x 106 PFU VV-CS. Eight days later, mice were challenged with 3.5 x 104 P. yoelii sporozoites and parasite-specific rRNA levels in the liver determined by quantitative RT-PCR. (b) Mice received WT or IFNKO TCR-Tg CD8+ T cells and were immunized as described for panel a. Eight days later, 2 x 106 purified TCR-Tg CD8+ spleen cells were recovered and retransferred into secondary naive BALB/c hosts that were subsequently challenged with 3.5 x 104 P. yoelii sporozoites. The parasite load in the liver was evaluated as for panel a. Each bar represents a single mouse. A Student t test was used to evaluate statistical significance.

Although the previous experiment demonstrates that primed IFNKO cells have intact antiparasite activity, the experimental design resulted in an unequal expansion of WT and IFNKO effector cells (Fig. 1). Therefore, we designed a second experiment to accurately control cell numbers and also discount other unidentified factors in immunized mice that could bias protective immunity. For this purpose, we purified activated CD8⁺ cells from the spleens of mice that had previously received either WT or IFNKO CD8⁺ T cells and were immunized as described above with VV-CS. Equal numbers of TCR-Tg cells (2 x 10⁶) were then transferred into new naive hosts, which were subsequently challenged with live parasites. In previous studies, we have determined that 2 x 10⁶ effector cells is the minimal number necessary to provide protection in naive mice (14). The results of these experiments showed that both WT and IFNKO effector CD8⁺ T cells were able to eliminate liver stage parasites with equal efficiency (Fig. 2b). Taken together, our data demonstrate that IFN- is not a critical mediator of protective cytotoxic T cells to reduce the parasite load in the liver.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The primary finding of our study is that protection afforded by CS-specific CD8⁺ T cells against viable P. yoelii liver stages is independent of their own production of IFN-. Our conclusions contrast with previous studies (5, 10, 16, 24, 28), which suggest that IFN- was critical for CD8⁺ T-cell-mediated protection. This apparent disagreement may be due to the involvement of other IFN--secreting cells in protective immunity, such as CD4⁺ T cells, which can produce IFN- and are known to directly inhibit the development of liver stages (4, 26). Moreover, IFN- is a pleiotropic cytokine that is known to modulate several aspects of antigen processing and MHC class I presentation (7, 21), and it also impacts on other cytokine networks (27), such that IFN--deficient mice used in other studies might exhibit altered protective responses even though CD8⁺ T cells themselves may not be the source of this cytokine. Indeed, we demonstrated here that CD8⁺ T-cell responses themselves are significantly reduced when these cells are unable to produce IFN- (Fig. 1a).

The specific antiparasitic determinant produced by CD8⁺ T cells in this process still remains to be identified. A previous study using the same transgenic system reported here used TCR-Tg CD8⁺ cells deficient in perforin or FasL or both and found that the protective effector mechanism was independent of these molecules (15). This was in agreement with studies showing that global ablation of perforin, Fas, and granzyme B did not affect protective immunity induced by attenuated sporozoites (5, 17). Other candidate effector molecules still remain to be evaluated, such as TNF-, although studies have demonstrated that the neutralization of TNF- does not alter protection (19). It is nonetheless clear that this inhibition of parasite development in our model is highly specific, as shown in our earlier studies where adoptively transferred TCR-Tg CD8⁺ T cells inhibited parasite development only after being activated by immunization with P. yoelii sporozoites or VV-CS and not the WT virus (20). Moreover, our recent studies using bone marrow chimeric mice demonstrate that adoptively transferred activated CD8⁺ TCR-Tg cells inhibit parasite development only when parenchymal liver cells express the appropriate class I MHC (H-2K^d), regardless of the MHC haplotype on bone marrow-derived cells (3).

It is possible that unconventional mechanisms of protection may be operating in this antimalaria model. It is also possible that this antiparasite effect is mediated by multiple redundant mechanisms, and thus an approach based on the elimination or neutralization of a single factor may not be informative. Finally, while our results indicate that IFN- is not necessary as an effector molecule mediating the direct protective effects of CD8⁺ T cells, our study cannot discount the possibility that IFN- is involved in complex cellular interactions where secretion by other cell types facilitates CD8⁺ T-cell-mediated elimination of liver-stage parasites.

 
This study was supported by National Institutes of Health grant number AI44375.

 
* Corresponding author. Mailing address: Department of Molecular Microbiology and Immunology, Malaria Research Institute, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe Street, Baltimore, MD 21205. Phone: (443) 287-1769. Fax: (410) 955-0105. E-mail: fzavala{at}jhsph.edu

Published ahead of print on 2 June 2008.

Editor: J. L. Flynn

Present address: Sanaria, Inc., 9800 Medical Center Drive, Rockville, MD 20850.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1
1. Bruna-Romero, O., J. C. Hafalla, G. Gonzalez-Aseguinolaza, G. Sano, M. Tsuji, and F. Zavala. 2001. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int. J. Parasitol. 31:1499-1502.[CrossRef][Medline]
2
2. Carvalho, L. H., J. C. Hafalla, and F. Zavala. 2001. ELISPOT assay to measure antigen-specific murine CD8⁺ T-cell responses. J. Immunol. Methods 252:207-218.[CrossRef][Medline]
3
3. Chakravarty, S., I. A. Cockburn, S. Kuk, M. G. Overstreet, J. B. Sacci, and F. Zavala. 2007. CD8⁺ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nat. Med. 13:1035-1041.[CrossRef][Medline]
4
4. Del Giudice, G., D. Grillot, L. Renia, I. Muller, G. Corradin, J. A. Louis, D. Mazier, and P. H. Lambert. 1990. Peptide-primed CD4⁺ cells and malaria sporozoites. Immunol. Lett. 25:59-63.[CrossRef][Medline]
5
5. Doolan, D. L., and S. L. Hoffman. 2000. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165:1453-1462.[Abstract/Free Full Text]
6
6. Ferreira, A., L. Schofield, V. Enea, H. Schellekens, P. van der Meide, W. E. Collins, R. S. Nussenzweig, and V. Nussenzweig. 1986. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 232:881-884.[Abstract/Free Full Text]
7
7. Fischer, A., S. Latour, and G. de Saint Basile. 2007. Genetic defects affecting lymphocyte cytotoxicity. Curr. Opin. Immunol. 19:348-353.[CrossRef][Medline]
8
8. Hoffman, S. L., D. Isenbarger, G. W. Long, M. Sedegah, A. Szarfman, S. Mellouk, and W. R. Ballou. 1990. T lymphocytes from mice immunized with irradiated sporozoites eliminate malaria from hepatocytes. Bull. W. H. O. 68(Suppl.):132-137.[Medline]
9
9. Hoffman, S. L., D. Isenbarger, G. W. Long, M. Sedegah, A. Szarfman, L. Waters, M. R. Hollingdale, P. H. van der Meide, D. S. Finbloom, and W. R. Ballou. 1989. Sporozoite vaccine induces genetically restricted T-cell elimination of malaria from hepatocytes. Science 244:1078-1081.[Abstract/Free Full Text]
10
10. Jobe, O., J. Lumsden, A. K. Mueller, J. Williams, H. Silva-Rivera, S. H. Kappe, R. J. Schwenk, K. Matuschewski, and U. Krzych. 2007. Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex class I-dependent interferon-gamma-producing CD8⁺ T cells. J. Infect. Dis. 196:599-607.[CrossRef][Medline]
11
11. Li, S., M. Rodrigues, D. Rodriguez, J. R. Rodriguez, M. Esteban, P. Palese, R. S. Nussenzweig, and F. Zavala. 1993. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8⁺ T-cell-mediated protective immunity against malaria. Proc. Natl. Acad. Sci. USA 90:5214-5218.[Abstract/Free Full Text]
12
12. Masopust, D., V. Vezys, A. L. Marzo, and L. Lefrancois. 2001. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291:2413-2417.[Abstract/Free Full Text]
13
13. Mellouk, S., R. K. Maheshwari, A. Rhodes-Feuillette, R. L. Beaudoin, N. Berbiguier, H. Matile, F. Miltgen, I. Landau, S. Pied, J. P. Chigot, et al. 1987. Inhibitory activity of interferons and interleukin 1 on the development of Plasmodium falciparum in human hepatocyte cultures. J. Immunol. 139:4192-4195.[Abstract]
14
14. Morrot, A., I. A. Cockburn, M. Overstreet, D. Rodriguez, and F. Zavala. 2006. Protective CD8⁺ T cells induced by malaria sporozoites do not undergo modulation of interleukin-7 receptor expression. Infect. Immun. 74:2495-2497.[Abstract/Free Full Text]
15
15. Morrot, A., and F. Zavala. 2004. Effector and memory CD8⁺ T cells as seen in immunity to malaria. Immunol. Rev. 201:291-303.[CrossRef][Medline]
16
16. Mueller, A. K., M. Deckert, K. Heiss, K. Goetz, K. Matuschewski, and D. Schluter. 2007. Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells. Am. J. Pathol. 171:107-115.[Abstract/Free Full Text]
17
17. Renggli, J., M. Hahne, H. Matile, B. Betschart, J. Tschopp, and G. Corradin. 1997. Elimination of Plasmodium berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity. Parasite Immunol. 19:145-148.[CrossRef][Medline]
18
18. Rodrigues, M., S. Li, K. Murata, D. Rodriguez, J. R. Rodriguez, I. Bacik, J. R. Bennink, J. W. Yewdell, A. Garcia-Sastre, R. S. Nussenzweig, et al. 1994. Influenza and vaccinia viruses expressing malaria CD8⁺ T and B-cell epitopes: comparison of their immunogenicity and capacity to induce protective immunity. J. Immunol. 153:4636-4648.[Abstract]
19
19. Rodrigues, M. M., A. S. Cordey, G. Arreaza, G. Corradin, P. Romero, J. L. Maryanski, R. S. Nussenzweig, and F. Zavala. 1991. CD8⁺ cytolytic T-cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int. Immunol. 3:579-585.[Abstract/Free Full Text]
20
20. Sano, G., J. C. Hafalla, A. Morrot, R. Abe, J. J. Lafaille, and F. Zavala. 2001. Swift development of protective effector functions in naive CD8⁺ T cells against malaria liver stages. J. Exp. Med. 194:173-180.[Abstract/Free Full Text]
21
21. Schoenborn, J. R., and C. B. Wilson. 2007. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 96:41-101.[Medline]
22
22. Schofield, L., A. Ferreira, R. Altszuler, V. Nussenzweig, and R. S. Nussenzweig. 1987. Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J. Immunol. 139:2020-2025.[Abstract]
23
23. Schofield, L., J. Villaquiran, A. Ferreira, H. Schellekens, R. Nussenzweig, and V. Nussenzweig. 1987. Gamma interferon, CD8⁺ T cells, and antibodies required for immunity to malaria sporozoites. Nature 330:664-666.[CrossRef][Medline]
24
24. Seguin, M. C., F. W. Klotz, I. Schneider, J. P. Weir, M. Goodbary, M. Slayter, J. J. Raney, J. U. Aniagolu, and S. J. Green. 1994. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei-infected mosquitoes: involvement of interferon gamma and CD8⁺ T cells. J. Exp. Med. 180:353-358.[Abstract/Free Full Text]
25
25. Tsuji, M., Y. Miyahira, R. S. Nussenzweig, M. Aguet, M. Reichel, and F. Zavala. 1995. Development of antimalaria immunity in mice lacking IFN-gamma receptor. J. Immunol. 154:5338-5344.[Abstract]
26
26. Tsuji, M., P. Romero, R. S. Nussenzweig, and F. Zavala. 1990. CD4⁺ cytolytic T cell clone confers protection against murine malaria. J. Exp. Med. 172:1353-1357.[Abstract/Free Full Text]
27
27. van Boxel-Dezaire, A. H., and G. R. Stark. 2007. Cell type-specific signaling in response to interferon-gamma. Curr. Top. Microbiol. Immunol. 316:119-154.[CrossRef][Medline]
28
28. Weiss, W. R., J. A. Berzofsky, R. A. Houghten, M. Sedegah, M. Hollindale, and S. L. Hoffman. 1992. A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J. Immunol. 149:2103-2109.[Abstract]

---

Infection and Immunity, August 2008, p. 3628-3631, Vol. 76, No. 8
0019-9567/08/$08.00+0     doi:10.1128/IAI.00471-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Trimnell, A., Takagi, A., Gupta, M., Richie, T. L., Kappe, S. H., Wang, R. (2009). Genetically Attenuated Parasite Vaccines Induce Contact-Dependent CD8+ T Cell Killing of Plasmodium yoelii Liver Stage-Infected Hepatocytes. J. Immunol. 183: 5870-5878 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chakravarty, S. Articles by Zavala, F. Search for Related Content PubMed PubMed Citation Articles by Chakravarty, S. Articles by Zavala, F.